BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32152628)

  • 1. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions.
    Akshintala S; Baldwin A; Liewehr DJ; Goodwin A; Blakeley JO; Gross AM; Steinberg SM; Dombi E; Widemann BC
    Neuro Oncol; 2020 Sep; 22(9):1368-1378. PubMed ID: 32152628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
    Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
    J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
    Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.
    Ly KI; Merker VL; Cai W; Bredella MA; Muzikansky A; Thalheimer RD; Da JL; Orr CC; Herr HP; Morris ME; Chang CY; Harris GJ; Plotkin SR; Jordan JT
    Neurology; 2023 Feb; 100(7):e661-e670. PubMed ID: 36332985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.
    Attia S; Guirguis M; Le LQ; Chhabra A
    Skeletal Radiol; 2024 Apr; 53(4):769-777. PubMed ID: 37903998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
    Dombi E; Solomon J; Gillespie AJ; Fox E; Balis FM; Patronas N; Korf BR; Babovic-Vuksanovic D; Packer RJ; Belasco J; Goldman S; Jakacki R; Kieran M; Steinberg SM; Widemann BC
    Neurology; 2007 Feb; 68(9):643-7. PubMed ID: 17215493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.
    Cai W; Steinberg SM; Bredella MA; Basinsky G; Somarouthu B; Plotkin SR; Solomon J; Widemann BC; Harris GJ; Dombi E
    Acad Radiol; 2018 Feb; 25(2):144-152. PubMed ID: 29097016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.
    Tucker T; Friedman JM; Friedrich RE; Wenzel R; Fünsterer C; Mautner VF
    J Med Genet; 2009 Feb; 46(2):81-5. PubMed ID: 18930997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
    Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1.
    Nguyen R; Dombi E; Widemann BC; Solomon J; Fuensterer C; Kluwe L; Friedman JM; Mautner VF
    Orphanet J Rare Dis; 2012 Oct; 7():75. PubMed ID: 23035791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
    Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
    PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.
    Higham CS; Dombi E; Rogiers A; Bhaumik S; Pans S; Connor SEJ; Miettinen M; Sciot R; Tirabosco R; Brems H; Baldwin A; Legius E; Widemann BC; Ferner RE
    Neuro Oncol; 2018 May; 20(6):818-825. PubMed ID: 29409029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiological manifestations of abdominopelvic nerve tumours seen in neurofibromatosis type 1.
    Ozcan HN; Karcaaltincaba M; Oguz B; Haliloglu M
    Clin Radiol; 2014 Apr; 69(4):431-5. PubMed ID: 24361143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.
    Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH
    Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
    Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
    J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1.
    Jett K; Nguyen R; Arman D; Birch P; Chohan H; Farschtschi S; Fuensterer C; Kluwe L; Friedman JM; Mautner VF
    Am J Med Genet A; 2015 Jul; 167(7):1518-24. PubMed ID: 25900062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.